Related references
Note: Only part of the references are listed.Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multidisciplinary care of cancer patients: a passing fad or here to stay?
John F. Thompson et al.
ANZ JOURNAL OF SURGERY (2019)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).
Maria Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial
Angela M. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G. A. McArthur et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial
Paul D. Brown et al.
LANCET ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
Anita Mahajan et al.
LANCET ONCOLOGY (2017)
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
K. A. Ahmed et al.
ANNALS OF ONCOLOGY (2016)
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial
Paul D. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease
James E. Bates et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Postoperative Stereotactic Radiosurgery to the Resection Cavity for Large Brain Metastases: Clinical Outcomes, Predictors of Intracranial Failure, and Implications for Optimal Patient Selection
Diane C. Ling et al.
NEUROSURGERY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Stereotactic radiosurgery (SRS) for brain metastases: a systematic review
Carsten Nieder et al.
RADIATION ONCOLOGY (2014)
Intracerebral metastases of malignant melanoma and their recurrences-A clinical analysis
Dorothea Miller et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
Surgical Resection of Brain Metastases-Impact on Neurological Outcome
Petra Schoedel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
Stereotactic Radiosurgery of the Postoperative Resection Cavity for Brain Metastases: Prospective Evaluation of Target Margin on Tumor Control
Clara Y. H. Choi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Linear accelerator based stereotactic radiosurgery for melanoma brain metastases
Mark E. Bernard et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Single brain metastases from melanoma: remarks on a series of 84 patients
Maurizio Salvati et al.
NEUROSURGICAL REVIEW (2012)
Ipilimumab in a Phase II trial of melanoma patients with brain metastases
Kim Margolin
ONCOIMMUNOLOGY (2012)
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens
V. Chiarion-Sileni et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Surgical management of melanoma brain metastases in patients treated with immunotherapy
Russell R. Lonser et al.
JOURNAL OF NEUROSURGERY (2011)
Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?
Won Seok Chang et al.
JOURNAL OF NEUROSURGERY (2010)
Factors affecting the outcome after treatment for metastatic melanoma to the brain
Christopher J. Carrubba et al.
SURGICAL NEUROLOGY (2009)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Determinants of outcome in melanoma patients with cerebral metastases
KM Fife et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades
AC Zacest et al.
JOURNAL OF NEUROSURGERY (2002)
Share Paper
